CANCER – REGENHEALTHSOLUTIONS (RHS)

PIER MARIA FORNASARI
2021-06-01

A Novel Form of Macrophage-based Immunotherapy Developed by Georgia State University Has the Potential to Revolutionize Cancer Treatment

A novel form of macrophage-based immunotherapy is effective at treating a broad spectrum of cancers, including those at advanced stages, according to a groundbreaking study led by Georgia State immunology professor Yuan Liu. Liu’s treatment works by leveraging macrophages, specialized white blood cells involved in the detection and elimination of cancer cells and other pathogens. Macrophages also activate

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2020-10-27

A published review by University of Texas MD Anderson Cancer Center outlines novel treatment approaches in Myelofibrosis

Their study outlines several treatments being investigated for the treatment of patients with myelofibrosis and other myeloproliferative neoplasms, generally after they have become resistant or intolerant to Janus kinase inhibition. A recent study outlines several treatments being investigated for the treatment of patients with myelofibrosis (MF) and other myeloproliferative neoplasms (MPNs), generally after they have become resistant or

No Comments InCANCER

PIER MARIA FORNASARI
2020-02-23

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

Immunotherapy has unleashed a revolution in care for some cancer patients. But most immunotherapies help only a small subset of patients, meaning doctors often have to resort to a trial-and-error process to determine who might actually benefit from the novel treatments. Now, scientists have developed a new metric they believe can help predict whether patients will respond

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2020-02-18

Nivolumab Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show

The immune checkpoint inhibitor nivolumab may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase 3 clinical trial suggest. A three-year survival analysis of the trial, called ATTRACTION-2 (NCT02267343), showed that the treatment significantly extended patients’ lives and the time they

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2020-02-11

Study identifies interaction that promotes cancerous state in cells

When the machinery that guides the transition of stem cells to somatic cells doesn’t shut down properly, cells can become cancerous. Identifying the mechanisms that impede those processes would offer scientists a target for cancer research. Purdue University scientists, led by Humaira Gowher, an associate professor in the Department of Biochemistry, have discovered the epigenetic process that

No Comments InCANCER

PIER MARIA FORNASARI
2020-02-07

CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial published on Science

In the first clinical study of its kind in the US, researchers used CRISPR to modify CAR T cells to make them more potent against cancer, but the clinical benefits are unknown. mmune cells altered by CRISPR are safe to use in cancer patients, according to results of a clinical trial reported February 6 in Science.

No Comments InCANCER CRISPR

PIER MARIA FORNASARI
2020-02-06

Viruses and cancer – systematic overview published by researchers of DKFZ

Scientists from the German Cancer Research Center systematically investigated the DNA of more than 2,600 tumour samples from patients with 38 different types of cancer to discover traces of viruses – which they found in 13 percent of the samples studied. The researchers also identified mechanisms that the pathogens use to trigger carcinogenic mutations in

No Comments InCANCER

PIER MARIA FORNASARI
2020-02-04

Blocking pro-fibrosis signaling pathway may improve immunotherapy of metastatic breast cancer

A Massachusetts General Hospital (MGH) research team has found that the overgrowth of connective called fibrosis may block the effectiveness of immunotherapies against metastatic breast cancer. Their report published in PNAS also finds that plerixafor, a drug approved to mobilize blood system stem cells in the treatment of lymphoma and multiple myeloma patients, can reduce fibrosis in

No Comments InCANCER

PIER MARIA FORNASARI
2020-02-03

Designing an emergency stop switch for immunotherapies

CAR T-cell therapy is a highly promising treatment strategy for tumors, but is associated with life-threatening side effects. Researchers at EPFL, UNIL and CHUV have developed a new way to “switch off” the therapy when a cancer patient’s life is in danger, paving the way for safer immunotherapy approaches to target solid tumors. Immunotherapy, unlike

No Comments InIMMUNOTHERAPY

PIER MARIA FORNASARI
2020-02-03

Mesoblast submits Ryoncil’s completed biologics license application to US FDA for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).

Mesoblast Limited today announced that it has submitted its completed Biologics License Application (BLA) to the United States Food and Drug Administration (US FDA) for Ryoncil™ (remestemcel-L), its lead allogeneic cell therapy for the treatment of children with steroid-refractory acute graft versus host disease (SRaGVHD). Mesoblast filed the final module of the rolling BLA submission,

No Comments InCANCER

REGENERATIVE AND PERSONALISED MEDICINE

DIGITAL HEALTHCARE

Category CANCER

A Novel Form of Macrophage-based Immunotherapy Developed by Georgia State University Has the Potential to Revolutionize Cancer Treatment

A published review by University of Texas MD Anderson Cancer Center outlines novel treatment approaches in Myelofibrosis

Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes

Nivolumab Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show

Study identifies interaction that promotes cancerous state in cells

CRISPR-Edited Cells for Cancer Therapy Safe in Humans: Trial published on Science

Viruses and cancer – systematic overview published by researchers of DKFZ

Blocking pro-fibrosis signaling pathway may improve immunotherapy of metastatic breast cancer

Designing an emergency stop switch for immunotherapies

Mesoblast submits Ryoncil’s completed biologics license application to US FDA for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD).